Samuel Rosner, MD

Stony Brook University, BS, Biology, 2013

Albert Einstein College of Medicine, MD, 2017

Johns Hopkins Bayview Medical Center, Internal Medicine Residency, 2020

Johns Hopkins Hospital, Medical Oncology Fellowship, 2023

Dr. Rosner is a thoracic oncologist with expertise in peri-operative clinical trial design and immunotherapeutic drug development for early and advanced non-small cell lung cancer (NSCLC). Currently, he serves as an assistant professor of medicine at the University of Maryland Marlene & Stewart Greenebaum Cancer Center. In his clinical role, he treats patients with thoracic malignancies. Prior to joining faculty at the University of Maryland, he completed his post-graduate oncology fellowship training at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center (SKCCC), during which time he served as Chief Oncology Fellow from 2022-2023.

One of Dr. Rosner's research goals focuses on improving peri-operative outcomes for patients with early-stage non-small cell lung cancer (NSCLC). Key research efforts in this treatment space include evaluating the role of immune checkpoint blockade in the perioperative management of early-stage NSCLC, as well as assessing the surrogacy of pathologic endpoints, such as pathological complete response (pCR), in terms of long-term clinical outcomes for patients who receive neoadjuvant therapy. Currently he is working closely with his multi-disciplinary colleagues to develop novel strategies that may further optimize and personalize our approaches in the early-stage disease setting. 

Dr. Rosner is also actively involved in the conception, design and implementation of early-phase clinical trials testing novel immunotherapeutic strategies for both early and advanced stage NSCLC. As a fellow, Dr. Rosner co-led a phase 1 investigator-initiated trial, testing the safety and immunogenicity of a novel KRAS-directed vaccine in advanced KRAS-mutated NSCLC. For his effort evaluating the immunologic responses of KRAS-mutant NSCLC, he was awarded the 2022 ASCO Young Investigator Award. In addition, his work evaluating the response of oncogene-driven NSCLC to neoadjuvant immune checkpoint blockade was recognized with an ASCO Merit award at the 2023 ASCO annual meeting. 

Dr. Rosner is an active member of the American Society of Clinical Oncology (ASCO) and International Association for the Study of Lung Cancer (IASLC). 

Lung cancer, Immune checkpoint blockade, neoadjuvant, KRAS-mutant NSCLC

Rosner S, Valdivia A, Hoe HJ, Murray JC, Levy B, Felip E, Solomon BJ. Antibody-Drug Conjugates for Lung Cancer: Payloads and Progress. Am Soc Clin Oncol Educ Book. 2023 May;43:e389968. doi: 10.1200/EDBK_389968. Review. PubMed PMID: 37163707.

Rosner S, Reuss JE, Zahurak M, Zhang J, Zeng Z, Taube J, Anagnostou V, Smith KN, Riemer J, Illei PB, Broderick SR, Jones DR, Topalian SL, Pardoll DM, Brahmer JR, Chaft JE, Forde PM. Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung Cancer. Clin Cancer Res. 2023 Feb 16;29(4):705-710. doi: 10.1158/1078-0432.CCR-22-2994. PubMed PMID: 36794455; PubMed Central PMCID: PMC9932577.

Rosner S, Liu C, Forde PM, Hu C. Association of Pathologic Complete Response and Long-Term Survival Outcomes Among Patients Treated With Neoadjuvant Chemotherapy or Chemoradiotherapy for NSCLC: A Meta-Analysis. JTO Clin Res Rep. 2022 Sep;3(9):100384. doi: 10.1016/j.jtocrr.2022.100384. eCollection 2022 Sep. PubMed PMID: 36118131; PubMed Central PMCID: PMC9472066.

Hwang M*, Canzoniero JV*, Rosner S*, Zhang G, White JR, Belcaid Z, Cherry C, Balan A, Pereira G, Curry A, Niknafs N, Zhang J, Smith KN, Sivapalan L, Chaft JE, Reuss JE, Marrone K, Murray JC, Li QK, Lam V, Levy BP, Hann C, Velculescu VE, Brahmer JR, Forde PM, Seiwert T, Anagnostou V. Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapy. J Immunother Cancer. 2022 Jun;10(6). doi: 10.1136/jitc-2022-004688. PubMed PMID: 35688557; PubMed Central PMCID: PMC9189831.